Main Menu

Poseida Therapeutics, Inc.

(NASDAQ GS: PSTX)

Rigrodsky Law, P.A. is investigating Poseida Therapeutics, Inc. (“Poseida”) regarding possible breaches of fiduciary duties and other violations of law related to Poseida’s agreement to be acquired by Roche Holdings, Inc. Under the terms of the agreement, Poseida shareholders will receive $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 12/11/2024


* Indicates a required field.

Back to Page